These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 23189852)

  • 41. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis.
    Cammà C; Cabibbo G; Bronte F; Enea M; Licata A; Attanasio M; Andriulli A; Craxì A
    J Hepatol; 2009 Oct; 51(4):675-81. PubMed ID: 19665247
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
    Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
    J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.
    Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
    Int J Infect Dis; 2011 Nov; 15(11):e740-6. PubMed ID: 21803628
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C.
    Brochot E; Riachi G; Plantier JC; Guillemard C; Vabret A; Mathurin P; Nguyen-Khac E; Duverlie G;
    J Med Virol; 2013 Jul; 85(7):1191-8. PubMed ID: 23918537
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
    He LL; Chen Z; Chen Y; Xu H; Tang H; Lei BJ; Lei XZ
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Retreatment of patients with chronic hepatitis C relapsers to a previous antiviral treatment.
    Floreani A; Cazzagon N; Furlan P; Baldovin T; Egoue J; Antoniazzi S; Baldo V; Minola E
    Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):711-5. PubMed ID: 21654322
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Telaprevir for retreatment of HCV infection.
    Zeuzem S; Andreone P; Pol S; Lawitz E; Diago M; Roberts S; Focaccia R; Younossi Z; Foster GR; Horban A; Ferenci P; Nevens F; Müllhaupt B; Pockros P; Terg R; Shouval D; van Hoek B; Weiland O; Van Heeswijk R; De Meyer S; Luo D; Boogaerts G; Polo R; Picchio G; Beumont M;
    N Engl J Med; 2011 Jun; 364(25):2417-28. PubMed ID: 21696308
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.
    Shirakawa H; Matsumoto A; Joshita S; Komatsu M; Tanaka N; Umemura T; Ichijo T; Yoshizawa K; Kiyosawa K; Tanaka E;
    Hepatology; 2008 Dec; 48(6):1753-60. PubMed ID: 18925643
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan.
    Lin JA; Chen YC; Cheng SN; Chen PJ; Chu HC; Hsieh TY; Shih YL
    J Formos Med Assoc; 2014 Oct; 113(10):727-33. PubMed ID: 24231092
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR.
    Bruno G; Fasano M; Saracino A; Volpe A; Bartolomeo N; Ladisa N; Maggi P; Monno L; Angarano G
    New Microbiol; 2015 Jan; 38(1):21-7. PubMed ID: 25742144
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment with pegylated interferon alpha-2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin.
    Carnicer F; Zapater P; Gutiérrez A; García A; Ruiz F; López M;
    Rev Esp Enferm Dig; 2005 May; 97(5):306-16. PubMed ID: 16004522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Persistent oxidative stress in patients with chronic active hepatitis-C infection after antiviral therapy failure.
    El-Kannishy G; Arafa M; Abdelaal I; Elarman M; El-Mahdy R
    Saudi J Gastroenterol; 2012; 18(6):375-9. PubMed ID: 23150023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life.
    Cento V; Barbaliscia S; Lenci I; Ruggiero T; Magni CF; Paolucci S; Babudieri S; Siciliano M; Pasquazzi C; Ciancio A; Perno CF; Ceccherini-Silberstein F;
    Clin Microbiol Infect; 2017 Oct; 23(10):777.e1-777.e4. PubMed ID: 28412381
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis C: retreatment and treatment of patients with renal failure.
    Chow WC
    J Gastroenterol Hepatol; 2000 May; 15 Suppl():E152-5. PubMed ID: 10921399
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Retreatment of chronic hepatitis C in previous non-responders and relapsers.
    Satoskar R; Jensen DM
    Expert Opin Pharmacother; 2007 Oct; 8(15):2491-503. PubMed ID: 17931085
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C.
    Martins EV; Gaburri AK; Gaburri D; Sementilli A
    Case Rep Gastroenterol; 2009 Nov; 3(3):366-371. PubMed ID: 21103255
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The new standard of HCV therapy: Retreatment in experienced patients.
    Gara N; Ghany MG
    Clin Liver Dis (Hoboken); 2012 Feb; 1(1):16-19. PubMed ID: 31186839
    [No Abstract]   [Full Text] [Related]  

  • 58. [Study on retreatment of CHC patients with initial treatment failure].
    Zhang L; Shen G; Zhang YL; Qiu GH; Lu Y; Zhao H; Yang M; Li MH; Xie Y; Cheng J; Xu DZ
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2012 Aug; 26(4):304-6. PubMed ID: 23189852
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].
    Liu JP; Kang Y; Shang J; Ding GQ; Xiao EH; Wei JF; Cao Q
    Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):656-8. PubMed ID: 24160338
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.
    Sagir A; Heintges T; Akyazi Z; Oette M; Erhardt A; Häussinger D
    Liver Int; 2007 Sep; 27(7):954-9. PubMed ID: 17696934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.